Multidrug-resistant tuberculosis and culture conversion with bedaquiline. - Wikidata - awgldk - TriplyDB

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

http://www.wikidata.org/entity/Q34434294

about

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Medical Management of Drug-Resistant Tuberculosis Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline.Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities Current strategies to treat tuberculosis Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis New anti-tuberculosis drugs and regimens: 2015 update A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Establishing Virulence Associated Polyphosphate Kinase 2 as a drug target for Mycobacterium tuberculosis Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.Insights into the pharmacokinetic properties of antitubercular drugs.Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Metabolic Perspectives on Persistence Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.Tuberculosis innovations mean little if they cannot save lives Update in Mycobacterium tuberculosis lung disease 2014.Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection.Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease Patients' Experience of Tuberculosis Treatment Using Directly Observed Treatment, Short-Course (DOTS): A Qualitative Study Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.Transmitted Extended-Spectrum Extensively Drug-Resistant Tuberculosis in Beijing, China, with Discordant Whole-Genome Sequencing Analysis Results.Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.

P2860

Q26741138-B1B6EFFC-C218-4000-B42C-C878A1D4CCC8 Q26764847-99FFCF21-413E-4730-92D4-047EEA27F645 Q26765394-2A3ADEA1-9561-49DE-9F2D-62E96809FA6C Q26771997-4A643216-0AF2-4706-B89C-ED18DA275C2F Q26801601-C1BF20A0-1AB0-463A-8B2E-95DBF378BA3F Q26824413-A5538182-EE7C-4DC2-BB6D-18DA2EE2D8D6 Q27003210-FDA1A550-4364-4004-9341-030E505E2B04 Q27311652-91100F19-0B32-4061-A4DA-9D5A1BFA798C Q27342142-0E1831AE-BA3D-4FA1-8D0D-A153DF871A09 Q28072205-8C981FD0-F7AC-4CCC-9774-91CD84AE8F39 Q28072376-ADFEED61-D2FC-4A45-A6D5-07930534C830 Q28075252-F5384FBB-7BB7-4E47-A232-DC3E093A3A6F Q28544800-C24138DB-FABC-4A76-8DCB-CAFC56CA248D Q28552438-58900C55-633B-49AC-A302-DF02D0A459D8 Q28554607-53DB00AE-1757-44E1-B71A-A23D8F3E6BEB Q28596775-CF88F76A-C5E8-434F-93CD-7D9DDB67987F Q28602112-05F15D35-CC5A-42D2-BF51-AD56B700F292 Q28828317-E963DED9-4F9E-44AD-9DA1-A5522CFC3A34 Q30236048-C59DA9E4-E3E5-46F6-AEE8-ED9BF4281B42 Q30249515-2CE18977-1B49-49CA-ADD6-E3C0ECB5BBB9 Q30251497-EB54035C-D0A2-49F3-9DBA-E10FFFCD4964 Q30275673-FB58565F-9C41-4809-BD0A-D0550D32321A Q30398195-58C97B81-C0DA-4D74-8E55-8D2696C751D1 Q30830344-0DF08330-C5C8-4832-A30B-04BD7ED77F42 Q33589758-3AC9778A-42F1-42AD-B29B-C8D9A15267B6 Q33599760-5059A9A5-24AD-4CFA-B561-9D06609161A5 Q33626683-EEF9EF20-1FB2-4033-B1BE-D94BEB7DC52A Q33627409-F86D68FF-979E-4463-A18A-492EC40743E2 Q33735642-6261D0BF-0C26-4C87-8D06-27BA62C2C81E Q33760793-C3FD7DB3-101F-4E86-97BC-D5EF78C1D016 Q33913678-5B12FA17-2611-4296-9395-61548240DC28 Q34596668-5117FE1D-1432-4C19-9A17-9C4433BB6B9E Q35167188-55F65AD7-76A1-4B70-A6AE-29E1EC4A5E19 Q35549372-DE36F07B-EA09-43E8-B332-BD216B85D34E Q35584122-78CA2982-70AE-4F6B-A31B-BAF3FCAC7C1B Q35645050-6B865D20-F5D9-4732-BA92-28A7BAB0908C Q35844546-D7C26F7B-4D68-45CE-9D42-5966712C815B Q35868609-A5ABEBEA-9E14-4BFE-8AB8-620A2A0577E3 Q35915044-B3169671-2DDD-4835-A75D-41773DB76AF7 Q36094215-F1112B2C-286B-43DC-AD7E-31DD451E2361

P2860

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

http://www.wikidata.org/entity/Q34434294

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@ast

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@en

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@nl

type

label

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@ast

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@en

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@nl

prefLabel

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@ast

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@en

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@nl

P1433

Q34434294-26CD73C0-2EB8-4117-A385-2E4A7E3F31FF

P1476

Q34434294-3793BE9B-1749-4EFF-8F78-3CA76CF4658E

P2093

Q34434294-0CF4265E-00D3-4FDD-BA9F-66B478ABF15F

Q34434294-186E2C77-E106-4E77-BEAD-A41E08472E79

Q34434294-2018DA17-A5E4-4F54-9CED-5718E1FD6A86

Q34434294-2D4B8883-D6C7-4E17-BB34-CCBF0C3637E0

Q34434294-2FBFE7D9-0D3D-4400-92DE-1C281051A209

Q34434294-5112E1B0-4EC0-4800-A9F2-28DEFB494FB3

Q34434294-5523AF13-9B8E-482A-B316-C8F7080B1369

Q34434294-5ABD2C68-496A-4AF2-8051-69819C69712B

Q34434294-6C1A872A-4815-40ED-B1FB-97B84D352A81

Q34434294-89414B3B-38FE-460B-A08A-EDDB260CC69B

P304

Q34434294-D74EFD45-83C8-4FD7-97B4-43CA3904FA68

P31

Q34434294-65D0AB3F-2FF8-4AE2-AEB3-8F4F185FB758

P356

Q34434294-99736D5A-9EB2-4076-B441-17533C3C9D6C

P407

Q34434294-164F248F-9069-402C-B558-8936DC41B19B

P433

Q34434294-F4282C9D-B970-480A-BAB7-5D3D546A12E3

P478

Q34434294-3CEA52A8-087A-4376-A48D-3276253029ED

P50

Q34434294-4772D260-8F6E-4054-BC18-A998539B4170

P577

Q34434294-CC087E9F-79E2-453C-9A70-68661E1E7129

P698

Q34434294-C943A0F6-C0B9-4DCB-ACF5-4BEF89B80F29

P921

Q34434294-1182325A-60DA-4433-8BEB-019CB3BF7D9F

Q34434294-A3AD72FD-4438-4B36-AEF0-742A583576A7

P356

P1433

The New England Journal of Medicine

P1476

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

@en

P2093

Alexander Pym

http://www.w3.org/2001/XMLSchema#string

Andreas H Diacon

http://www.w3.org/2001/XMLSchema#string

Brian Dannemann

http://www.w3.org/2001/XMLSchema#string

Eduardo Gotuzzo

http://www.w3.org/2001/XMLSchema#string

Els De Paepe

http://www.w3.org/2001/XMLSchema#string

Irina Vasilyeva

http://www.w3.org/2001/XMLSchema#string

Jorge M de los Rios

http://www.w3.org/2001/XMLSchema#string

Koen Andries

http://www.w3.org/2001/XMLSchema#string

Myriam Haxaire-Theeuwes

http://www.w3.org/2001/XMLSchema#string

Nacer Lounis

http://www.w3.org/2001/XMLSchema#string

P304

723-732

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1313865

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Martin Peter Grobusch

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25140958

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance